ASX:TLXBiotechs
Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After New Trial Data Plans And Regeneron Collaboration
Telix Pharmaceuticals (ASX:TLX) has drawn fresh attention after announcing plans to showcase OPTIMAL-PSMA 2 data on its TLX597-Tx candidate, alongside upcoming TLX591-Tx trial results and a new collaboration with Regeneron Pharmaceuticals.
See our latest analysis for Telix Pharmaceuticals.
These clinical updates and the Regeneron partnership arrive during a period of strong share price momentum, with Telix recording a 15.03% 1 month share price return and a 35.38% 3 month share price return,...